Skip to content

Study · Animal study (in vivo) · mouse · 2025

3 results

Acute Nicotinamide Adenine Dinucleotide Supplementation via Nicotinamide Mononucleotide Does Not Rescue Functional Impairment in a Lipopolysaccharide-induced Delirium Mouse Model.

Chui MKK, Ashok Kumaar PV, Schilling B, Verdin E, Newman JC

The journals of gerontology. Series A, Biological sciences and medical sciences1 Jun 2025

PMID40445730 (opens in a new tab)PMCIDPMC12239633 (opens in a new tab)DOI10.1093/gerona/glaf116 (opens in a new tab)PepBankPUB-40445730
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In a mouse delirium model, acute NMN supplementation did not rescue delirium-like sickness behavior.

    In plain wordsIn mice with induced delirium, acute NMN did not restore sickness behavior.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeDelirium-like sickness behavior
    Study

    mousen: not reported in source

    lipopolysaccharide-induced delirium mouse model
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    While Nicotinamide adenine dinucleotide did not rescue the delirium-like sickness behavior and metabolic dysfunction in mice
    1 context sentence
    Summary · context
    In this study, we investigate the effect of acute supplementation of nicotinamide mononucleotide, a direct precursor of Nicotinamide adenine dinucleotide, in a lipopolysaccharide-induced delirium mouse model.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In a mouse delirium model, acute NMN supplementation did not rescue metabolic dysfunction.

    In plain wordsIn mice with induced delirium, acute NMN did not restore metabolic function.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeMetabolic dysfunction
    Study

    mousen: not reported in source

    lipopolysaccharide-induced delirium mouse model
    Outcome group
    Energy expenditure and thermogenesis · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    While Nicotinamide adenine dinucleotide did not rescue the delirium-like sickness behavior and metabolic dysfunction in mice
    1 context sentence
    Summary · context
    In this study, we investigate the effect of acute supplementation of nicotinamide mononucleotide, a direct precursor of Nicotinamide adenine dinucleotide, in a lipopolysaccharide-induced delirium mouse model.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In a mouse delirium model, NMN supplementation rescued plasma IFNγ levels.

    In plain wordsIn mice with induced delirium, NMN restored blood IFNγ levels.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    Not applicablePlasma IFNgamma
    Study

    mousen: not reported in source

    lipopolysaccharide-induced delirium mouse model
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    a comprehensive cytokine profile analysis did reveal rescue of plasma IFNγ levels by nicotinamide mononucleotide supplementation and partial improvement on the levels of IL-12p40, RANTES, LIX, and IL-17 which were sex-dependent.
    1 context sentence
    Summary · context
    In this study, we investigate the effect of acute supplementation of nicotinamide mononucleotide, a direct precursor of Nicotinamide adenine dinucleotide, in a lipopolysaccharide-induced delirium mouse model.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.